 Jennifer Goldman
Concepts (293)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-Bacterial Agents | 35 | 2024 | 243 | 10.840 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 12 | 2024 | 39 | 5.380 |
Why?
| | Humans | 89 | 2024 | 6896 | 4.120 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 8 | 2023 | 13 | 3.790 |
Why?
| | Child | 58 | 2024 | 3364 | 3.480 |
Why?
| | Respiratory Insufficiency | 4 | 2023 | 13 | 3.080 |
Why?
| | Trimethoprim | 6 | 2024 | 11 | 2.840 |
Why?
| | Hospitals, Pediatric | 11 | 2024 | 187 | 2.840 |
Why?
| | Schools | 10 | 2024 | 56 | 2.770 |
Why?
| | Retrospective Studies | 26 | 2024 | 1296 | 2.320 |
Why?
| | Vancomycin | 4 | 2021 | 17 | 2.160 |
Why?
| | Stevens-Johnson Syndrome | 7 | 2020 | 14 | 2.150 |
Why?
| | Pharmacovigilance | 5 | 2024 | 8 | 2.130 |
Why?
| | Drug Monitoring | 4 | 2021 | 13 | 2.080 |
Why?
| | Anti-Infective Agents | 5 | 2023 | 21 | 2.000 |
Why?
| | Electronic Health Records | 7 | 2021 | 64 | 1.890 |
Why?
| | Female | 25 | 2024 | 3525 | 1.550 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 4 | 2022 | 16 | 1.510 |
Why?
| | Adolescent | 20 | 2024 | 2197 | 1.480 |
Why?
| | Male | 24 | 2024 | 3337 | 1.450 |
Why?
| | Adverse Drug Reaction Reporting Systems | 5 | 2024 | 13 | 1.370 |
Why?
| | Child, Preschool | 18 | 2024 | 1569 | 1.370 |
Why?
| | Students | 3 | 2024 | 34 | 1.320 |
Why?
| | Fluoroquinolones | 2 | 2021 | 3 | 1.320 |
Why?
| | Cross Infection | 3 | 2019 | 12 | 1.310 |
Why?
| | Acute Kidney Injury | 2 | 2021 | 30 | 1.260 |
Why?
| | Ambulatory Care | 3 | 2023 | 45 | 1.250 |
Why?
| | Pneumonia | 3 | 2022 | 32 | 1.170 |
Why?
| | Prospective Studies | 8 | 2024 | 525 | 1.160 |
Why?
| | Staphylococcus aureus | 3 | 2016 | 18 | 1.150 |
Why?
| | Neoplasms | 2 | 2021 | 128 | 1.140 |
Why?
| | Antifungal Agents | 2 | 2017 | 13 | 1.120 |
Why?
| | Vulnerable Populations | 2 | 2023 | 7 | 1.090 |
Why?
| | Anti-Infective Agents, Urinary | 2 | 2016 | 4 | 1.070 |
Why?
| | Microsomes, Liver | 3 | 2016 | 44 | 1.070 |
Why?
| | Respiratory Tract Infections | 3 | 2024 | 85 | 1.060 |
Why?
| | Nurse's Role | 4 | 2024 | 10 | 1.050 |
Why?
| | Medicaid | 4 | 2024 | 38 | 1.040 |
Why?
| | Pediatrics | 4 | 2018 | 186 | 1.000 |
Why?
| | Risk Factors | 8 | 2021 | 487 | 0.890 |
Why?
| | Penicillins | 2 | 2024 | 8 | 0.880 |
Why?
| | Documentation | 2 | 2020 | 6 | 0.880 |
Why?
| | Pharmacy Service, Hospital | 2 | 2020 | 8 | 0.860 |
Why?
| | Tandem Mass Spectrometry | 2 | 2022 | 20 | 0.840 |
Why?
| | Ambulatory Care Facilities | 3 | 2020 | 36 | 0.830 |
Why?
| | Pneumococcal Infections | 2 | 2019 | 6 | 0.830 |
Why?
| | Streptococcus pneumoniae | 2 | 2019 | 5 | 0.830 |
Why?
| | Infusions, Intravenous | 3 | 2023 | 26 | 0.830 |
Why?
| | Health Care Costs | 2 | 2019 | 33 | 0.820 |
Why?
| | Severity of Illness Index | 2 | 2021 | 149 | 0.820 |
Why?
| | United States | 16 | 2024 | 669 | 0.810 |
Why?
| | Education, Distance | 1 | 2022 | 6 | 0.800 |
Why?
| | Urban Population | 1 | 2022 | 27 | 0.800 |
Why?
| | Osteomyelitis | 1 | 2021 | 8 | 0.790 |
Why?
| | Drug Utilization | 3 | 2017 | 15 | 0.790 |
Why?
| | Etoposide | 1 | 2021 | 11 | 0.780 |
Why?
| | Antiviral Agents | 2 | 2023 | 30 | 0.780 |
Why?
| | Fear | 1 | 2021 | 17 | 0.770 |
Why?
| | Bacterial Infections | 1 | 2021 | 27 | 0.750 |
Why?
| | Antineoplastic Agents | 1 | 2021 | 55 | 0.750 |
Why?
| | Bacteremia | 3 | 2015 | 25 | 0.740 |
Why?
| | Hospital Mortality | 2 | 2019 | 22 | 0.720 |
Why?
| | Patient Readmission | 2 | 2021 | 68 | 0.690 |
Why?
| | Clostridium Infections | 1 | 2019 | 7 | 0.680 |
Why?
| | Endophthalmitis | 1 | 2019 | 1 | 0.670 |
Why?
| | Eye Pain | 1 | 2019 | 1 | 0.670 |
Why?
| | Causality | 1 | 2019 | 10 | 0.670 |
Why?
| | Infusions, Parenteral | 1 | 2019 | 5 | 0.670 |
Why?
| | Intensive Care, Neonatal | 1 | 2019 | 7 | 0.670 |
Why?
| | Cefazolin | 1 | 2018 | 2 | 0.650 |
Why?
| | Preoperative Care | 1 | 2018 | 26 | 0.650 |
Why?
| | Antibiotic Prophylaxis | 1 | 2018 | 30 | 0.640 |
Why?
| | Emergency Service, Hospital | 2 | 2020 | 130 | 0.630 |
Why?
| | Patient Discharge | 1 | 2019 | 57 | 0.630 |
Why?
| | Guideline Adherence | 2 | 2017 | 36 | 0.630 |
Why?
| | Arthritis, Juvenile | 2 | 2015 | 31 | 0.590 |
Why?
| | Staphylococcal Infections | 2 | 2015 | 21 | 0.590 |
Why?
| | Home Infusion Therapy | 1 | 2017 | 2 | 0.580 |
Why?
| | Drug Prescriptions | 1 | 2017 | 20 | 0.570 |
Why?
| | Bacterial Typing Techniques | 1 | 2016 | 4 | 0.570 |
Why?
| | Staphylococcal Skin Infections | 1 | 2016 | 3 | 0.570 |
Why?
| | Paragonimiasis | 1 | 2016 | 1 | 0.560 |
Why?
| | Praziquantel | 1 | 2016 | 1 | 0.560 |
Why?
| | Anthelmintics | 1 | 2016 | 2 | 0.560 |
Why?
| | Hospitalization | 3 | 2021 | 210 | 0.560 |
Why?
| | Proteins | 1 | 2016 | 27 | 0.550 |
Why?
| | Eosinophilia | 1 | 2016 | 29 | 0.540 |
Why?
| | Adult | 5 | 2023 | 1181 | 0.520 |
Why?
| | Enterococcus faecalis | 1 | 2015 | 1 | 0.520 |
Why?
| | Gentamicins | 1 | 2015 | 5 | 0.510 |
Why?
| | Gram-Positive Bacterial Infections | 1 | 2015 | 8 | 0.510 |
Why?
| | Gastrointestinal Diseases | 1 | 2016 | 45 | 0.510 |
Why?
| | Medication Therapy Management | 1 | 2015 | 8 | 0.500 |
Why?
| | Length of Stay | 6 | 2022 | 233 | 0.480 |
Why?
| | Vancomycin Resistance | 1 | 2014 | 4 | 0.470 |
Why?
| | Cross-Sectional Studies | 8 | 2024 | 336 | 0.460 |
Why?
| | Missouri | 2 | 2024 | 81 | 0.450 |
Why?
| | Practice Guidelines as Topic | 3 | 2020 | 108 | 0.440 |
Why?
| | Biomarkers | 3 | 2014 | 136 | 0.440 |
Why?
| | Surveys and Questionnaires | 5 | 2023 | 274 | 0.420 |
Why?
| | Pharmaceutical Preparations | 3 | 2023 | 37 | 0.410 |
Why?
| | Hot Temperature | 1 | 2012 | 6 | 0.410 |
Why?
| | Erythema | 1 | 2012 | 5 | 0.410 |
Why?
| | Enteral Nutrition | 1 | 2012 | 63 | 0.390 |
Why?
| | Infant | 5 | 2019 | 1446 | 0.360 |
Why?
| | Drug Therapy, Combination | 2 | 2021 | 35 | 0.360 |
Why?
| | Acute Disease | 2 | 2021 | 79 | 0.360 |
Why?
| | Reproducibility of Results | 2 | 2022 | 199 | 0.350 |
Why?
| | Inappropriate Prescribing | 3 | 2020 | 27 | 0.350 |
Why?
| | Pandemics | 4 | 2023 | 82 | 0.340 |
Why?
| | Inpatients | 2 | 2022 | 44 | 0.340 |
Why?
| | Pharmacogenetics | 4 | 2020 | 176 | 0.320 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2021 | 94 | 0.320 |
Why?
| | Diagnosis, Differential | 2 | 2019 | 77 | 0.300 |
Why?
| | Program Evaluation | 2 | 2020 | 45 | 0.300 |
Why?
| | Hospital Costs | 2 | 2019 | 29 | 0.300 |
Why?
| | Biotransformation | 3 | 2016 | 49 | 0.290 |
Why?
| | Venous Thromboembolism | 2 | 2018 | 13 | 0.290 |
Why?
| | Young Adult | 2 | 2021 | 647 | 0.280 |
Why?
| | Area Under Curve | 3 | 2021 | 35 | 0.280 |
Why?
| | Outpatients | 2 | 2024 | 27 | 0.270 |
Why?
| | Patient Safety | 2 | 2023 | 20 | 0.260 |
Why?
| | Age Factors | 2 | 2016 | 210 | 0.260 |
Why?
| | Infant, Newborn | 2 | 2019 | 816 | 0.240 |
Why?
| | Virus Diseases | 1 | 2024 | 16 | 0.240 |
Why?
| | Cohort Studies | 4 | 2022 | 289 | 0.240 |
Why?
| | School Nursing | 1 | 2024 | 5 | 0.240 |
Why?
| | beta-Lactams | 1 | 2024 | 2 | 0.230 |
Why?
| | Macrolides | 1 | 2024 | 9 | 0.230 |
Why?
| | Sulfonamides | 1 | 2024 | 10 | 0.230 |
Why?
| | Midwestern United States | 1 | 2024 | 34 | 0.230 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2024 | 65 | 0.230 |
Why?
| | Aminoglycosides | 1 | 2023 | 16 | 0.230 |
Why?
| | Common Data Elements | 1 | 2023 | 2 | 0.230 |
Why?
| | Hospitals | 2 | 2020 | 36 | 0.220 |
Why?
| | Drug Interactions | 2 | 2024 | 32 | 0.210 |
Why?
| | Efficiency, Organizational | 1 | 2022 | 3 | 0.210 |
Why?
| | Coinfection | 1 | 2022 | 7 | 0.210 |
Why?
| | Plasma | 1 | 2022 | 7 | 0.210 |
Why?
| | Pneumonia, Aspiration | 1 | 2022 | 8 | 0.210 |
Why?
| | HLA-B7 Antigen | 1 | 2022 | 2 | 0.200 |
Why?
| | HLA-C Antigens | 1 | 2022 | 3 | 0.200 |
Why?
| | HLA-B Antigens | 1 | 2022 | 7 | 0.200 |
Why?
| | Community-Institutional Relations | 1 | 2022 | 5 | 0.200 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2022 | 40 | 0.200 |
Why?
| | Academic Medical Centers | 1 | 2022 | 11 | 0.200 |
Why?
| | School Health Services | 1 | 2022 | 9 | 0.200 |
Why?
| | Child, Hospitalized | 2 | 2022 | 26 | 0.200 |
Why?
| | Influenza, Human | 1 | 2023 | 68 | 0.200 |
Why?
| | Microbiological Techniques | 1 | 2021 | 5 | 0.190 |
Why?
| | Data Collection | 2 | 2020 | 29 | 0.190 |
Why?
| | Bronchiolitis | 1 | 2021 | 10 | 0.190 |
Why?
| | Patient Acuity | 1 | 2020 | 7 | 0.180 |
Why?
| | Leadership | 1 | 2020 | 12 | 0.180 |
Why?
| | Biological Availability | 2 | 2017 | 8 | 0.180 |
Why?
| | Obesity | 2 | 2023 | 125 | 0.180 |
Why?
| | Safety | 1 | 2020 | 14 | 0.180 |
Why?
| | Communication | 1 | 2020 | 46 | 0.180 |
Why?
| | Health Services Needs and Demand | 1 | 2020 | 15 | 0.180 |
Why?
| | Patient Care Team | 1 | 2020 | 19 | 0.180 |
Why?
| | Nursing Staff, Hospital | 1 | 2020 | 20 | 0.170 |
Why?
| | Drug Eruptions | 1 | 2019 | 3 | 0.170 |
Why?
| | Pharmacists | 1 | 2019 | 4 | 0.170 |
Why?
| | Safety Management | 2 | 2020 | 6 | 0.170 |
Why?
| | Skin | 1 | 2019 | 15 | 0.170 |
Why?
| | Linear Models | 1 | 2019 | 56 | 0.170 |
Why?
| | Acetylcysteine | 2 | 2016 | 9 | 0.170 |
Why?
| | Vitrectomy | 1 | 2019 | 1 | 0.170 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2019 | 7 | 0.170 |
Why?
| | Probability | 1 | 2019 | 15 | 0.170 |
Why?
| | Time Factors | 1 | 2020 | 250 | 0.170 |
Why?
| | Microbial Sensitivity Tests | 2 | 2021 | 33 | 0.160 |
Why?
| | Washington | 1 | 2018 | 11 | 0.160 |
Why?
| | Drug Hypersensitivity | 1 | 2018 | 19 | 0.160 |
Why?
| | Drug Utilization Review | 2 | 2015 | 6 | 0.160 |
Why?
| | General Surgery | 1 | 2018 | 19 | 0.160 |
Why?
| | Risk Assessment | 1 | 2019 | 137 | 0.160 |
Why?
| | Protein Binding | 1 | 2018 | 31 | 0.160 |
Why?
| | Nephrotic Syndrome | 1 | 2018 | 29 | 0.160 |
Why?
| | Clinical Trials as Topic | 2 | 2016 | 45 | 0.160 |
Why?
| | Algorithms | 1 | 2019 | 105 | 0.160 |
Why?
| | Nurses | 1 | 2018 | 9 | 0.160 |
Why?
| | Expert Testimony | 1 | 2018 | 3 | 0.150 |
Why?
| | Clindamycin | 1 | 2017 | 3 | 0.150 |
Why?
| | Insurance Claim Review | 1 | 2017 | 2 | 0.150 |
Why?
| | Organ Transplantation | 1 | 2017 | 6 | 0.140 |
Why?
| | Bone Marrow Transplantation | 1 | 2017 | 17 | 0.140 |
Why?
| | Models, Statistical | 1 | 2017 | 29 | 0.140 |
Why?
| | Penicillin-Binding Proteins | 1 | 2016 | 2 | 0.140 |
Why?
| | Soft Tissue Infections | 2 | 2016 | 12 | 0.140 |
Why?
| | Reagent Kits, Diagnostic | 1 | 2016 | 13 | 0.140 |
Why?
| | Pediatric Nurse Practitioners | 1 | 2016 | 4 | 0.140 |
Why?
| | Practice Patterns, Nurses' | 1 | 2016 | 5 | 0.140 |
Why?
| | Education, Nursing, Continuing | 1 | 2016 | 3 | 0.140 |
Why?
| | Child Health Services | 1 | 2016 | 24 | 0.140 |
Why?
| | Opportunistic Infections | 1 | 2016 | 7 | 0.140 |
Why?
| | Nalidixic Acid | 1 | 2016 | 1 | 0.140 |
Why?
| | DNA Gyrase | 1 | 2016 | 1 | 0.140 |
Why?
| | Topoisomerase II Inhibitors | 1 | 2016 | 1 | 0.140 |
Why?
| | Sensitivity and Specificity | 1 | 2016 | 150 | 0.140 |
Why?
| | Drug Resistance, Bacterial | 1 | 2016 | 14 | 0.140 |
Why?
| | Databases, Factual | 3 | 2024 | 108 | 0.130 |
Why?
| | Hospitalists | 1 | 2015 | 7 | 0.130 |
Why?
| | Drug Resistance, Microbial | 1 | 2015 | 2 | 0.130 |
Why?
| | Methylation | 1 | 2015 | 11 | 0.130 |
Why?
| | Oxidation-Reduction | 1 | 2015 | 9 | 0.130 |
Why?
| | In Vitro Techniques | 1 | 2015 | 23 | 0.130 |
Why?
| | Congresses as Topic | 3 | 2020 | 9 | 0.130 |
Why?
| | Animals | 1 | 2016 | 729 | 0.110 |
Why?
| | Vomiting | 1 | 2012 | 23 | 0.110 |
Why?
| | Diarrhea | 1 | 2012 | 18 | 0.110 |
Why?
| | Nod2 Signaling Adaptor Protein | 1 | 2012 | 3 | 0.100 |
Why?
| | Crohn Disease | 1 | 2012 | 25 | 0.100 |
Why?
| | Gastroparesis | 1 | 2012 | 4 | 0.100 |
Why?
| | Gastric Bypass | 1 | 2012 | 8 | 0.100 |
Why?
| | Folic Acid | 1 | 2011 | 17 | 0.100 |
Why?
| | Reference Values | 1 | 2011 | 39 | 0.100 |
Why?
| | Methotrexate | 1 | 2011 | 30 | 0.100 |
Why?
| | Aging | 1 | 2011 | 39 | 0.090 |
Why?
| | Appendectomy | 1 | 2012 | 100 | 0.090 |
Why?
| | Genotype | 1 | 2011 | 410 | 0.090 |
Why?
| | Appendicitis | 1 | 2012 | 115 | 0.090 |
Why?
| | International Cooperation | 2 | 2020 | 9 | 0.080 |
Why?
| | Incidence | 2 | 2019 | 133 | 0.080 |
Why?
| | Focus Groups | 1 | 2024 | 12 | 0.060 |
Why?
| | Acceleration | 1 | 2023 | 4 | 0.060 |
Why?
| | Cross-Over Studies | 1 | 2023 | 35 | 0.060 |
Why?
| | Nursing Homes | 1 | 2023 | 3 | 0.050 |
Why?
| | Educational Status | 1 | 2023 | 21 | 0.050 |
Why?
| | Polypharmacy | 1 | 2023 | 3 | 0.050 |
Why?
| | Research Design | 1 | 2023 | 63 | 0.050 |
Why?
| | Policy | 1 | 2022 | 3 | 0.050 |
Why?
| | Treatment Failure | 1 | 2022 | 16 | 0.050 |
Why?
| | Minority Groups | 1 | 2022 | 17 | 0.050 |
Why?
| | Disabled Children | 1 | 2022 | 8 | 0.050 |
Why?
| | Cytochrome P-450 CYP2D6 | 1 | 2024 | 184 | 0.050 |
Why?
| | Pilot Projects | 1 | 2021 | 120 | 0.050 |
Why?
| | Hypersensitivity | 1 | 2021 | 56 | 0.050 |
Why?
| | Global Health | 1 | 2020 | 15 | 0.040 |
Why?
| | Computer Communication Networks | 1 | 2020 | 2 | 0.040 |
Why?
| | Canada | 1 | 2020 | 31 | 0.040 |
Why?
| | Liver Function Tests | 1 | 2019 | 4 | 0.040 |
Why?
| | Europe | 1 | 2020 | 37 | 0.040 |
Why?
| | Anti-Inflammatory Agents | 1 | 2019 | 11 | 0.040 |
Why?
| | Registries | 1 | 2020 | 92 | 0.040 |
Why?
| | Anticonvulsants | 1 | 2019 | 25 | 0.040 |
Why?
| | Administration, Cutaneous | 1 | 2019 | 4 | 0.040 |
Why?
| | Antipsychotic Agents | 1 | 2019 | 14 | 0.040 |
Why?
| | Attitude of Health Personnel | 1 | 2020 | 42 | 0.040 |
Why?
| | Practice Patterns, Physicians' | 1 | 2020 | 85 | 0.040 |
Why?
| | Intensive Care Units | 1 | 2018 | 17 | 0.040 |
Why?
| | North America | 1 | 2018 | 44 | 0.040 |
Why?
| | Logistic Models | 1 | 2018 | 84 | 0.040 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2018 | 10 | 0.040 |
Why?
| | Steroids | 1 | 2018 | 16 | 0.040 |
Why?
| | Survival Analysis | 1 | 2018 | 50 | 0.040 |
Why?
| | Prevalence | 1 | 2018 | 146 | 0.040 |
Why?
| | Interdisciplinary Communication | 1 | 2018 | 9 | 0.040 |
Why?
| | Hospital Charges | 1 | 2018 | 11 | 0.040 |
Why?
| | Early Diagnosis | 1 | 2018 | 17 | 0.040 |
Why?
| | Health Resources | 1 | 2018 | 17 | 0.040 |
Why?
| | Cost of Illness | 1 | 2018 | 19 | 0.040 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2017 | 5 | 0.040 |
Why?
| | Delphi Technique | 1 | 2017 | 11 | 0.040 |
Why?
| | Orosomucoid | 1 | 2017 | 1 | 0.040 |
Why?
| | Serum Albumin | 1 | 2017 | 9 | 0.040 |
Why?
| | Injections, Intravenous | 1 | 2017 | 15 | 0.040 |
Why?
| | Consensus | 1 | 2017 | 35 | 0.040 |
Why?
| | Drug Administration Schedule | 1 | 2017 | 35 | 0.040 |
Why?
| | Drug Dosage Calculations | 1 | 2017 | 16 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2017 | 30 | 0.040 |
Why?
| | Body Weight | 1 | 2017 | 52 | 0.040 |
Why?
| | Pregnancy | 1 | 2018 | 216 | 0.040 |
Why?
| | Aged | 1 | 2018 | 378 | 0.040 |
Why?
| | Sinusitis | 1 | 2016 | 5 | 0.040 |
Why?
| | Otitis Media | 1 | 2016 | 8 | 0.030 |
Why?
| | Urinary Tract Infections | 1 | 2016 | 21 | 0.030 |
Why?
| | Hospital Bed Capacity | 1 | 2016 | 3 | 0.030 |
Why?
| | Pharyngitis | 1 | 2016 | 16 | 0.030 |
Why?
| | Body Mass Index | 1 | 2017 | 157 | 0.030 |
Why?
| | Virulence Factors | 1 | 2015 | 4 | 0.030 |
Why?
| | Quality Improvement | 1 | 2016 | 60 | 0.030 |
Why?
| | C-Reactive Protein | 1 | 2015 | 16 | 0.030 |
Why?
| | Treatment Outcome | 1 | 2018 | 622 | 0.030 |
Why?
| | Hemoglobins | 1 | 2015 | 27 | 0.030 |
Why?
| | Chromatography, Liquid | 1 | 2014 | 9 | 0.030 |
Why?
| | ROC Curve | 1 | 2012 | 22 | 0.030 |
Why?
| | Polymerase Chain Reaction | 1 | 2012 | 84 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2012 | 215 | 0.020 |
Why?
| | Enzymes | 1 | 2011 | 4 | 0.020 |
Why?
| | Drug Therapy | 1 | 2011 | 7 | 0.020 |
Why?
| | Carrier Proteins | 1 | 2011 | 35 | 0.020 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2011 | 96 | 0.020 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|